How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Duchenne Muscular Dystrophy Drugs Market
- By Drug Class: Exon Skipping Therapies, Gene Therapy, Corticosteroids, Stop Codon Read-Through Agents, Utrophin Modulators
- By Mechanism of Action: Dystrophin Restoration, Inflammation Reduction, Muscle Regeneration Enhancement, Fibrosis Inhibition
- By Route of Administration: Intravenous Injection, Oral Administration, Intramuscular Injection
- By Patient Age Group: Pediatric Patients, Adolescent Patients, Adult Patients
- By Treatment Purpose: Disease-Modifying Therapies, Symptomatic Treatment, Supportive Care
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Exon Skipping Therapies leads By Drug Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 10 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the Duchenne Muscular Dystrophy Drugs Market report
A complete, evidence-based study - 12 chapters and 116 sections covering market size, segmentation across 5 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Drug Class 5
Mechanism of Action 4
Route of Administration 3
Patient Age Group 3
Treatment Purpose 3
Companies profiled
Sarepta Therapeutics
Pfizer
Roche
Solid Biosciences
NS Pharma (Nippon Shinyaku)
PTC Therapeutics
Catabasis Pharmaceuticals
Wave Life Sciences
Biogen
Bristol-Myers Squibb
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Sarepta Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Pfizer
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Roche
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Solid Biosciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →NS Pharma (Nippon Shinyaku)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →PTC Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Catabasis Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Wave Life Sciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Biogen
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Bristol-Myers Squibb
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$9,724M by 2033 · 10.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Exon Skipping Therapies41.6
- Gene Therapy17.8
- Corticosteroids19.4
- Stop Codon Read-Through Agents9.8
- Utrophin Modulators11.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,416M → $3,149M · 10.5%
Europe$986.9M → $2,361M · 11.5%
Asia Pacific$901.1M → $1,831M · 9.3%
Latin America$557.8M → $1,188M · 9.9%
Middle East and Africa$429.1M → $942.0M · 10.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.732026
10.722027
10.742028
10.752029
10.772030
10.772031
10.782032
10.802033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Sarepta Therapeutics13.5
- Pfizer16.3
- Roche11.6
- Solid Biosciences15.0
- NS Pharma (Nippon Shinyaku)7.0
- PTC Therapeutics8.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Class31.0%
Mechanism of Action12.3%
Route of Administration16.5%
Patient Age Group13.1%
Treatment Purpose27.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.2
- Europe24.9
- Asia Pacific19.3
- Latin America12.5
- Middle East and Africa9.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics | 75 | 89 | 99 | 86 | 83 | 95 | 88 |
| Pfizer | 82 | 87 | 89 | 70 | 91 | 75 | 82 |
| Roche | 73 | 83 | 70 | 77 | 88 | 84 | 79 |
| Solid Biosciences | 71 | 65 | 58 | 59 | 76 | 66 | 66 |
| NS Pharma (Nippon Shinyaku) | 52 | 53 | 59 | 72 | 77 | 71 | 64 |
| PTC Therapeutics | 71 | 64 | 59 | 71 | 57 | 70 | 65 |
| Catabasis Pharmaceuticals | 41 | 48 | 45 | 48 | 57 | 49 | 48 |
| Wave Life Sciences | 41 | 53 | 35 | 36 | 50 | 60 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Sarepta Therapeutics
- Pfizer
- Roche
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Sarepta Therapeutics | − | ◐ | ✓ | ✓ | ✓ | ✓ |
| Pfizer | ◐ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Roche | ◐ | ◐ | ✓ | ◐ | ✓ | ◐ |
| Solid Biosciences | ◐ | ◐ | − | − | ◐ | ◐ |
| NS Pharma (Nippon Shinyaku) | − | ◐ | − | ✓ | ✓ | ◐ |
| PTC Therapeutics | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Catabasis Pharmaceuticals | − | − | − | − | − | − |
| Wave Life Sciences | ◐ | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Sarepta Therapeutics88
2Pfizer82
3Roche79
4Solid Biosciences66
5PTC Therapeutics65
6NS Pharma (Nippon Shinyaku)64
7Catabasis Pharmaceuticals48
8Wave Life Sciences46
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Sarepta TherapeuticsPfizerRoche
Contender3
Focused players with pockets of strength.
Solid BiosciencesNS Pharma (Nippon Shinyaku)PTC Therapeutics
Niche2
Specialists in a single segment or region.
Catabasis PharmaceuticalsWave Life Sciences
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Class in North America, then scale across Duchenne Muscular Dystrophy Drugs Market — a $694M beachhead inside a $9.85B market.
Beachhead (SOM)$694Mobtainable near-term
Serviceable (SAM)$3.65Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Exon Skipping Therapies
Best fit — highest urgency & budget in Drug Class.
Economic buyer78 fit
Gene Therapy
Strong fit — clear ROI and a fast path to value.
End user68 fit
Corticosteroids
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Mechanism of Action & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel31%
Digital / self-serve20%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Drug Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Duchenne Muscular Dystrophy Drugs Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified20%
Evaluation13%
Closed-won6%
$8.6KCAC
$51KLTV
6.0:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Duchenne Muscular Dystrophy Drugs Market is a resilient opportunity — $4.08B by 2033, compounding at 4.9%.
TAM · 2025$2.79Btoday
TAM · 2033$4.08Bforecast
CAGR4.9%2027–2033
Cumulative$30.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.08BTotal addressable market
SAM$1.71BServiceable available market
SOM$340MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.9% CAGR
Demand compounds through 2033, outpacing GDP across Drug Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Class moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.08BLarge & growingTAM by 2033 at 4.9% CAGR
$1.71BServiceable nowreachable with today’s model
$340MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.18BBear3.2% CAGR
$4.08BBase4.9% CAGR
$5.22BBull6.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Mechanism of Action optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Duchenne Muscular Dystrophy Drugs Market — a $5.58B market by 2033. Plan: grow share from 8.5% to 14.1%.
Market size · 2033$5.58Btotal addressable
Market CAGR4.9%2027–2033
Target share14.1%from 8.5% today
Revenue ambition$787Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.5% | 14.1% | On track |
| Revenue | $478M | $787M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 29.4% | 39.7% | Behind |
| Customer retention | 87.2% | 93.5% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Mechanism of Action capability
A defensible second engine — invest in Mechanism of Action to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Mechanism of Action
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $116M capacity & capability investment
- Greenlight bolt-on M&A in Mechanism of Action
- Authorise North America expansion plan
- Fund R&D program for Drug Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Duchenne Muscular Dystrophy Drugs Market conversation — a $6.62B market you can size, segment and defend in minutes.
Market size · 2033$6.62Btotal opportunity
Growth8.4%CAGR to 2033
Addressable buyers1,491+accounts in scope
Typical ROI7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Class
Goal Grow share in Drug Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7×return on cost, year one
< 3 mopayback period
$92K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
Sarepta TherapeuticsPfizerRocheSolid BiosciencesNS Pharma (Nippon Shinyaku)PTC TherapeuticsCatabasis PharmaceuticalsWave Life Sciences+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Duchenne Muscular Dystrophy Drugs Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Duchenne Muscular Dystrophy Drugs Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →NK Cells Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportNatural Killer (NK) Cell Therapeutics Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportCombined hormonal contraceptive Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportSerum Cancer Biomarkers Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportInterleukin Inhibitors Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportBurn Care Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportDrugs for Oral Mucositis Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportMedical Specimen Bags Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportForskolin Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportGummy Supplement Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportBinge Eating Disorder Drug Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportChemotherapy-Induced Neutropenia Treatment Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.